Table 1 Percentage of cells in the G1 phase of the cell cycle, in control and dasatinib treated samples.
From: Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Cell Lines | Control | 50 nM Dasatinib | 100 nM Dasatinib | 200 nM Dasatinib |
|---|---|---|---|---|
HT144 | 51.6 ± 4.5 | 58.3 ± 1.2 | 59.6 ± 2.1 | 59.4 ± 6.1 |
Lox-IMVI | 35.4 ± 3.0 | 51.0 * ± 4.6 | 56.6 * ± 4.6 | 53.0 * ± 6.6 |
Malme-3M | 71.7 ± 1.5 | 70.2 ± 4.0 | 70.9 ± 2.0 | 69.5 ± 2.4 |
Sk-Mel-5 | 57.6 ± 1.6 | 55.3 ± 2.2 | 57.6 ± 3.3 | 58.9 ± 4.3 |